首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Tackling quantitative polymorphic analysis through fixed-dose combination tablets production. Pyrazinamide polymorphic assessment
【24h】

Tackling quantitative polymorphic analysis through fixed-dose combination tablets production. Pyrazinamide polymorphic assessment

机译:通过固定剂组合片生产来解决定量多态性分析。 吡嗪酰胺多态评估

获取原文
获取原文并翻译 | 示例
           

摘要

Pyrazinamide (PZA), Rifampicin (RIF), Isoniazid (ISH) and Ethambutol (ETB) form the core for the treatment of Tuberculosis, today a devastating disease in low-income populations around the world. These drugs are usually administrated by fixed-dose combination (FDC) products, to favour the patient compliance and prevent bacterial resistance.
机译:吡嗪酰胺(PZA)、利福平(RIF)、异烟肼(ISH)和乙胺丁醇(ETB)构成了结核病治疗的核心。如今,结核病是全世界低收入人群的一种毁灭性疾病。这些药物通常通过固定剂量组合(FDC)产品给药,以促进患者的依从性并防止细菌耐药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号